Preceding findings demonstrate a higher expression of CEA (98–100 %) and uPAR (90–96 %) in pancreatic adenocarcinoma to our findings; however, this slight discrepancy is not likely to alter the final conclusion of this study [33, 35, 48]. The gene discussed is CEACAM3; the disease is pancreatic adenocarcinoma.